Form 4: Protagonist Therapeutics Director Exercises Stock Options
SEC Form 4 Filing
Harold E. Selick, a director at Protagonist Therapeutics, exercised stock options to acquire 6,490 shares of common stock at $1.89 per share on March 7, 2024.
Summary
- On March 7, 2024, Harold E. Selick, a director of Protagonist Therapeutics, Inc., exercised stock options.
- This transaction involved the acquisition of 6,490 shares of common stock at a price of $1.89 per share.
- Following the transaction, Selick directly owns 27,996 shares of Protagonist Therapeutics.
- The stock option was fully vested and the expiration date is October 22, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine transaction by a company director. It doesn't inherently indicate positive or negative performance for the company.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction may have a minor impact on shareholders by slightly increasing the number of outstanding shares.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of transaction: Director exercised stock options to acquire common stock. |
| 10/22/2024 | Expiration date of the stock option. |
| 03/11/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.